Ident. | Authors (with country if any) | Title |
---|
000310 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
000349 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease |
000558 |
Anne-Sophie Rolland [France] ; Carine Karachi [France] ; Marie-Paule Muriel [France] ; Etienne C. Hirsch [France] ; Chantal Francois [France] | Internal Pallidum and Substantia Nigra Control Different Parts of the Mesopontine Reticular Formation in Primate |
000A88 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease |
000B92 |
Pershia Samadi [Canada] ; Marc Morissette [Canada] ; Daniel Levesque [Canada] ; Thérèse Di Paolo [Canada] | BDNF Levels Are Not Related with Levodopa-Induced Dyskinesias in MPTP Monkeys |
000D83 |
Glenda Halliday [Australie] ; Maria Trinidad Herrero [Espagne] ; Karen Murphy [Australie] ; Heather Mccann [Australie] ; Francisco Ros-Bemal [Espagne] ; Carlos Barcia [Espagne] ; Hideo Mori [Japon] ; Francisco J. Blesa [Espagne] ; José A. Obeso [Espagne] | No Lewy Pathology in Monkeys with Over 10 Years of Severe MPTP Parkinsonism |
000F02 |
Carine Karachi [France] ; David Grabli [France] ; Nicolas Baup [France] ; Stéphanie Mounayar [France] ; Dominique Tande [France] ; Chantal Francois [France] ; Etienne C. Hirsch [France] | Dysfunction of the Subthalamic Nucleus Induces Behavioral and Movement Disorders in Monkeys |
001211 |
Jose L. Lanciego [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Francisco J. Blesa [Espagne] ; Lydia Alvarez-Erviti [Espagne] ; Jorge Guridi [Espagne] ; Pedro Barroso-Chinea [Espagne] ; Yoland Smith [États-Unis] ; Jose A. Obeso [Espagne] | Lesion of the Centromedian Thalamic Nucleus in MPTP-Treated Monkeys |
001451 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
001452 |
Christopher D. Herzog [États-Unis] ; Biplob Dass [États-Unis] ; James E. Holden [États-Unis] ; James Iii Stansell [États-Unis] ; Mehdi Gasmi [États-Unis] ; Mark H. Tuszynski [États-Unis] ; Raymond T. Bartus [États-Unis] ; Jeffrey H. Kordower [États-Unis] | Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys |
001946 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
001E69 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
002391 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
002450 |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
002457 |
Jay S. Schneider [États-Unis] ; Timothy V. Wade [États-Unis] | Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy |
002514 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
002582 |
Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |
002585 |
Louis C. Tan [États-Unis] ; Peter H. Protell [États-Unis] ; J. William Langston [États-Unis] ; Daniel M. Togasaki [États-Unis] | The Hyperkinetic Abnormal Movements Scale: A tool for measuring levodopa-induced Abnormal Movements in squirrel monkeys |
002590 |
Rebecka Klintenberg [Suède] ; Lars Gunne [Suède] ; Per E. Andren [Suède] | Tardive dyskinesia model in the common marmoset |
002601 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
002673 |
J. A. Biittner-Ennever [Allemagne] ; A. K. E. Horn [Allemagne] | Oculomotor system: A dual innervation of the eye muscles from the abducens, trochlear, and oculomotor nuclei |
002680 |
Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France] | Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence |
002851 |
Mikko Kuoppam Ki [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Michael Jackson [Royaume-Uni] ; Lance Smith [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa |
002864 |
Frans Vanderwerf [Pays-Bas] ; Catherine Buisseret-Delmas [France] ; Pierre Buisseret [France] | Afferent innervation of eyelids and their connections to the superior colliculus |
002916 |
G. M. Petzinger [États-Unis] ; M. Quik [États-Unis] ; E. Ivashina [États-Unis] ; M. W. Jakowec [États-Unis] ; M. Jakubiak [États-Unis] ; D. Di Monte [États-Unis] ; J. W. Langston [États-Unis] | Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate |
002944 |
R. E. Yee [États-Unis] ; I. Irwin [États-Unis] ; C. Milonas [États-Unis] ; D. B. Stout [États-Unis] ; S-C. Huang [États-Unis] ; K. Shoghi-Jadid [États-Unis] ; N. Satyamurthy [États-Unis] ; L. E. Delanney [États-Unis] ; D. M. Togasaki [États-Unis] ; K. F. Farahani [États-Unis] ; K. Delfani [États-Unis] ; A. M. Janson [États-Unis] ; M. E. Phelps [États-Unis] ; J. W. Langston [États-Unis] ; J. R. Barrio [États-Unis] | Novel observations with FDOPA-PET imaging after early nigrostriatal damage |
002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
002969 |
L. Munro-Davies [Royaume-Uni] ; J. Winter [Royaume-Uni] ; T. Z. Aziz [Royaume-Uni] ; J. Stein [Royaume-Uni] | Kainate acid lesions of the pedunculopontine region in the normal behaving primate |
002A90 |
I. Ghorayeb [France] ; P. O. Fernagut [France] ; I. Aubert [France] ; E. Bezard [France] ; Werner Poewe [Autriche] ; G. K. Wenning [Autriche] ; F. Tison [France] | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration |
002B26 |
D. A. Di Monte [États-Unis] ; A. Mccormack [États-Unis, Suède] ; G. Petzinger [États-Unis] ; A. M. Janson [États-Unis, Suède] ; M. Quik [États-Unis] ; W. J. Langston [États-Unis] | Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model |
002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
002C25 |
S. Palfi [États-Unis] ; L. Leventhal [États-Unis] ; C. G. Goetz [États-Unis] ; P. Hantraye [France] ; B.-Z. Roitberg [États-Unis] ; J. Sramek [États-Unis] ; M. Emborg [États-Unis] ; J. H. Kordower [États-Unis] | Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys |
002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
002D35 |
J. M. Brotchie [Royaume-Uni] ; S. H. Fox [Royaume-Uni] | Quantitative assessment of dyskinesias in subhuman primates |
002D79 |
K. S. Topp [États-Unis] ; N. N. Byl [États-Unis] | Movement dysfunction following repetitive hand opening and closing : Anatomical analysis in owl monkeys |
002D97 |
R. K. B. Pearce [Royaume-Uni] | L-dopa and dyskinesias in normal monkeys |
002F49 |
H. Bergman [Israël] ; A. Raz [Israël] ; A. Feingold [Israël] ; A. Nini [Israël] ; I. Nelken [Israël] ; D. Hansel [France] ; H. Ben-Pazi [Israël] ; A. Reches [Israël] | Physiology of MPTP tremor |
003027 |
J. S. Schneider [États-Unis] ; A. Pope-Coleman [États-Unis] ; M. Van Velson [États-Unis] ; F. Menzaghi [États-Unis] ; G. K. Lloyd [États-Unis] | Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys |
003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
003085 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; T. N. Chase [États-Unis] | Amantadine reduces levodopa-induced dyskinesias in Parkinsonian monkeys |
003128 |
L. Rioux [États-Unis] ; P. A. Frohna [États-Unis] ; J. N. Joyce [États-Unis] ; J. S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
003383 |
J. A. Vilensky [États-Unis] ; S. Gilman ; R. J. Morecraft | DC60 : An example of one of the 450 cases that compose the Denny-Brown collection of primate lesion material |
003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
003512 |
R. K. B. Pearce [Royaume-Uni] ; M. Jackson [Royaume-Uni] ; L. Smith [Royaume-Uni] ; P. Jenner ; C. D. Marsden | Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus) |
003564 |
R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas] | The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys |
003671 |
I. Rektor [France] ; M. Svejdova ; C. Silva-Barrat ; C. Menini | The cholinergic system-dependent myoclonus of the baboon Papio papio is a reticular reflex myoclonus |
003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
003759 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
003779 |
I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. Gunne | Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey |
003819 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
003864 |
R. Kurlan [États-Unis] ; M. H. Kim ; D. M. Gash | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys : assessment with a new rating scale for monkey parkinsonism |
003867 |
S. Brailowsky | Myoclonus in Papio papio |
003903 |
J. M. Brotchie ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate |
003922 |
N. M. J. Rupniak ; S. J. Tye ; M. J. Steventon ; S. Boyce ; S. D. Iversen | Spontaneous orofacial dyskinesias in a captive cynomolgus monkey : implications for tardive dyskinesia |
003937 |
I. J. Mitchell ; R. Luquin ; S. Boyce ; C. E. Clarke ; R. G. Robertson ; M. A. Sambrook ; A. R. Crossman | Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia |
003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
003985 |
W. R. G. Gibb ; M. Terruli ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Jenner ; C. D. Marsden | The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
003A90 |
J. G. De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M. A. Mena ; J. Reiriz ; J. C. Bustos ; C. Magarinos ; A. Martinez | Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease |
003A97 |
N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |